Mendus Achieves Large-Scale GMP Manufacturing Milestone for Vididencel Cell Therapy in AML and CML
核心洞察
Mendus (搜索) successfully established large-scale GMP production of vididencel through its strategic manufacturing alliance with NorthX Biologics (搜索), marking a critical milestone for advanced clinical development.
The achievement secures reliable supply of clinical-grade material to support upcoming late-stage trials in acute myeloid leukemia (AML) and chronic myeloid leukemia (CML).
Vididencel is designed as a post-remission immunotherapy to activate anti-leukemic immune responses against residual disease while preserving patient health and quality of life.
Mendus (搜索) AB, a Swedish-Dutch biopharmaceutical company focused on immunotherapies targeting tumor recurrence, has successfully established large-scale GMP production of its lead cell therapy product vididencel through its strategic manufacturing alliance with NorthX Biologics (搜索). The milestone represents a critical advancement in the company's clinical development strategy for acute myeloid leukemia (AML) and chronic myeloid leukemia (CML).
Manufacturing Alliance Delivers Critical Infrastructure
The achievement culminates a transformative collaboration initiated in 2023 when Mendus (搜索) and NorthX Biologics (搜索) entered into a strategic manufacturing alliance for large-scale production of vididencel. The project, co-financed by leading life science investor Flerie (搜索), was specifically designed to support late-stage clinical development and future commercialization of the immunotherapy.
"With the establishment of large-scale GMP production, we deliver on an important milestone for the vididencel program," said Erik Manting, Chief Executive Officer of Mendus (搜索). "Reliable manufacturing is central to advance our clinical trials and go-to-market strategy in AML and CML. This milestone demonstrates the maturity of the vididencel production process and strength of our partnership with NorthX Biologics (搜索)."
The successful establishment of GMP production confirms the robustness and reproducibility of the manufacturing process in a large-scale GMP environment, securing the supply of clinical-grade material to support Mendus (搜索)' advanced clinical development program while positioning NorthX Biologics (搜索) as a potential commercial supplier.
Advanced Cell Therapy Development
Vididencel functions as a post-remission immunotherapy designed to activate anti-leukemic immune responses against residual disease while preserving health and quality of life. The therapy represents an off-the-shelf cellular immunotherapy approach for acute and chronic myeloid leukemias.
Following positive Phase 2 proof-of-concept data demonstrating durable clinical remissions in AML, Mendus (搜索) is expanding clinical development of vididencel in both AML and CML, according to the updated clinical strategy communicated on October 2, 2025. The securing of consistent GMP supply marks the transition of Mendus towards a late-stage, clinical execution-focused company.
Strategic Collaboration Impact
For two years, NorthX Biologics (搜索) and Mendus (搜索) collaborated closely to adapt NorthX Biologics' GMP facilities for allogeneic cell therapy production, perform technology transfer of the vididencel process, and manufacture clinical batches in accordance with stringent regulatory standards.
"This partnership has gone beyond traditional manufacturing," said Janet Hoogstraate, Chief Executive Officer of NorthX Biologics (搜索). "Through open, transparent collaboration, we have built not just a cell therapy infrastructure but mutual capabilities. Together, we have grown stronger, technically, operationally, and strategically. Achieving GMP readiness and delivering clinical-grade material for Mendus (搜索)' advanced clinical pipeline is a shared success story rooted in trust and innovation."
The successful execution positions both companies at the forefront of Europe's advanced therapy medicinal products (ATMP) ecosystem and reinforces Sweden's position as a hub for ATMPs. The collaboration exemplifies how tailored contract development and manufacturing organization (CDMO) alliances can unlock clinical and commercial potential for cell therapies by aligning scientific ambition with industrial excellence.